title: Sertraline versus other antidepressive agents for depression.
abstract: BACKGROUND
  The National Institute for Health and Clinical Excellence clinical practice guideline on the treatment of depressive disorder recommended that selective serotonin reuptake inhibitors should be the first-line option when drug therapy is indicated for a depressive episode. Preliminary evidence suggested that sertraline might be slightly superior in terms of effectiveness.
  
  
  OBJECTIVE
  To assess the evidence for the efficacy, acceptability and tolerability of sertraline in comparison with tricyclics (TCAs), heterocyclics, other SSRIs and newer agents in the acute-phase treatment of major depression.
  
  
  METHODS
  MEDLINE (1966 to 2008), EMBASE (1974 to 2008), the Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register and the Cochrane Central Register of Controlled Trials up to July 2008. No language restriction was applied. Reference lists of relevant papers and previous systematic reviews were hand-searched. Pharmaceutical companies and experts in this field were contacted for supplemental data.
  
  
  METHODS
  Randomised controlled trials allocating patients with major depression to sertraline versus any other antidepressive agent.
  
  
  METHODS
  Two review authors independently extracted data. Discrepancies were resolved with another member of the team. A double-entry procedure was employed by two reviewers. Information extracted included study characteristics, participant characteristics, intervention details and outcome measures in terms of efficacy (the number of patients who responded or remitted), acceptability (the number of patients who failed to complete the study) and tolerability (side-effects).
  
  
  RESULTS
  A total of 59 studies, mostly of low quality, were included in the review, involving multiple treatment comparisons between sertraline and other antidepressant agents. Evidence favouring sertraline over some other antidepressants for the acute phase treatment of major depression was found, either in terms of efficacy (fluoxetine) or acceptability/tolerability (amitriptyline, imipramine, paroxetine and mirtazapine). However, some differences favouring newer antidepressants in terms of efficacy (mirtazapine) and acceptability (bupropion) were also found. In terms of individual side effects, sertraline was generally associated with a higher rate of participants experiencing diarrhoea.
  
  
  CONCLUSIONS
  This systematic review and meta-analysis highlighted a trend in favour of sertraline over other antidepressive agents both in terms of efficacy and acceptability, using 95% confidence intervals and a conservative approach, with a random effects analysis. However, the included studies did not report on all the outcomes that were pre-specified in the protocol of this review. Outcomes of clear relevance to patients and clinicians were not reported in any of the included studies.
authors.affiliation: Department of Medicine and Public Health, Section of Psychiatry and Clinical Psychology, University of Verona, Policlinico "G.B.Rossi", Piazzale L.A. Scuro, 10, Verona, Italy, 37134.
authors.forename: Andrea
authors.initials: A
authors.lastname: Cipriani
authors.forename: Teresa
authors.initials: T
authors.lastname: La Ferla
authors.forename: Toshi A
authors.initials: TA
authors.lastname: Furukawa
authors.forename: Alessandra
authors.initials: A
authors.lastname: Signoretti
authors.forename: Atsuo
authors.initials: A
authors.lastname: Nakagawa
authors.forename: Rachel
authors.initials: R
authors.lastname: Churchill
authors.forename: Hugh
authors.initials: H
authors.lastname: McGuire
authors.forename: Corrado
authors.initials: C
authors.lastname: Barbui
mesh_terms: D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003863:Depression / Q000188:drug therapy*; D003967:Diarrhea / Q000139:chemically induced; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D020280:Sertraline / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000928:Antidepressive Agents; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline
references.citation: JAMA. 2002 Apr 10;287(14):1807-14
references.pmid: 11939866
references.citation: Cochrane Database Syst Rev. 2000;(4):CD002791
references.pmid: 11034764
references.citation: Int Clin Psychopharmacol. 1993 Fall;8(3):197-202
references.pmid: 8263318
references.citation: Eur Psychiatry. 1999 Mar;14(1):41-8
references.pmid: 10572324
references.citation: Am J Psychiatry. 2005 Oct;162(10):1957-60
references.pmid: 16199844
references.citation: J Clin Psychopharmacol. 2005 Oct;25(5):471-5
references.pmid: 16160624
references.citation: J Clin Psychiatry. 1997 Nov;58(11):484-91
references.pmid: 9413414
references.citation: Can J Psychiatry. 2004 Sep;49(9):601-6
references.pmid: 15503731
references.citation: Cochrane Database Syst Rev. 2010 Mar 17;(3):CD006114
references.pmid: 20238342
references.citation: CMAJ. 2004 Feb 17;170(4):477-80
references.pmid: 14970094
references.citation: Int Clin Psychopharmacol. 1997 Nov;12(6):323-31
references.pmid: 9547134
references.citation: Pharmacopsychiatry. 1998 Sep;31(5):170-7
references.pmid: 9832348
references.citation: Eur J Clin Pharmacol. 2004 Nov;60(9):629-34
references.pmid: 15448956
references.citation: Ann Clin Psychiatry. 1999 Dec;11(4):205-15
references.pmid: 10596735
references.citation: J Clin Psychiatry. 1990 Jun;51 Suppl:51-7; discussion 58-9
references.pmid: 2189875
references.citation: Cochrane Database Syst Rev. 2009 Jul 08;(3):CD006529
references.pmid: 19588396
references.citation: J Clin Psychiatry. 1990 Dec;51 Suppl B:18-27
references.pmid: 2258378
references.citation: Cochrane Database Syst Rev. 2007;(2):
references.pmid: 25267891
references.citation: Ann Pharmacother. 2004 Apr;38(4):579-85
references.pmid: 14982982
references.citation: Clin Ther. 2000 Apr;22(4):411-9
references.pmid: 10823363
references.citation: Arch Gen Psychiatry. 1962 Dec;7:407-17
references.pmid: 13931376
references.citation: Stat Med. 2002 Aug 30;21(16):2313-24
references.pmid: 12210616
references.citation: Curr Med Res Opin. 2007 Feb;23(2):245-50
references.pmid: 17288677
references.citation: Arch Gen Psychiatry. 1991 Apr;48(4):319-23
references.pmid: 2009033
references.citation: Int J Epidemiol. 2002 Feb;31(1):72-6
references.pmid: 11914297
references.citation: Neuropsychopharmacology. 2003 Mar;28(3):552-7
references.pmid: 12629536
references.citation: J Clin Epidemiol. 2006 Nov;59(11):1125-6
references.pmid: 17027421
references.citation: Psychopharmacology (Berl). 2004 Oct;175(4):399-406
references.pmid: 15042278
references.citation: Int Psychogeriatr. 2001 Mar;13(1):75-84
references.pmid: 11352337
references.citation: Am J Psychiatry. 2000 May;157(5):729-36
references.pmid: 10784465
references.citation: J Clin Psychiatry. 1995 Jun;56(6):229-37
references.pmid: 7775364
references.citation: J Clin Psychopharmacol. 2000 Dec;20(6):645-52
references.pmid: 11106136
references.citation: J Clin Psychiatry. 1996;57 Suppl 2:53-62
references.pmid: 8626364
references.citation: Curr Med Res Opin. 2006 Sep;22(9):1703-13
references.pmid: 16968574
references.citation: Encephale. 2002 Jul-Aug;28(4):343-9
references.pmid: 12232543
references.citation: J Affect Disord. 2000 Apr;58(1):19-36
references.pmid: 10760555
references.citation: Pharmacopsychiatry. 2000 Nov;33(6):206-12
references.pmid: 11147927
references.citation: BMJ. 1999 May 1;318(7192):1180-4
references.pmid: 10221945
references.citation: JAMA. 2003 Aug 20;290(7):921-8
references.pmid: 12928469
references.citation: Cochrane Database Syst Rev. 2005 Oct 19;(4):CD004185
references.pmid: 16235353
references.citation: JAMA. 2002 Aug 14;288(6):701-9
references.pmid: 12169073
references.citation: Br J Psychiatry. 1979 Apr;134:382-9
references.pmid: 444788
references.citation: J Clin Epidemiol. 2006 Jan;59(1):7-10
references.pmid: 16360555
references.citation: J Clin Psychopharmacol. 2003 Aug;23(4):358-64
references.pmid: 12920411
references.citation: Pharmacopsychiatry. 2004 May;37(3):93-7
references.pmid: 15179966
references.citation: Ann Intern Med. 1992 Jan 1;116(1):78-84
references.pmid: 1530753
references.citation: J Clin Psychiatry. 1990 Dec;51 Suppl B:28-33
references.pmid: 2258379
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2003 May;27(3):493-500
references.pmid: 12691786
references.citation: Turk Psikiyatri Derg. 2005 Fall;16(3):153-63
references.pmid: 16180148
references.citation: Acta Psychiatr Belg. 1995 May-Jun;95(3):139-51
references.pmid: 8525856
references.citation: JAMA. 2002 Apr 10;287(14):1853-4
references.pmid: 11939872
references.citation: Lancet. 2004 Apr 24;363(9418):1341-5
references.pmid: 15110490
references.citation: Cochrane Database Syst Rev. 2008 Oct 08;(4):CD000448
references.pmid: 18843608
references.citation: Pharmacopsychiatry. 2005 Mar;38(2):78-86
references.pmid: 15744631
references.citation: Br J Psychiatry. 2003 Aug;183:102-4
references.pmid: 12893662
references.citation: J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
references.pmid: 14399272
references.citation: Stat Methods Med Res. 2008 Jun;17(3):279-301
references.pmid: 17925316
references.citation: Br J Psychiatry. 1999 Apr;174:297-303
references.pmid: 10533547
references.citation: J Pharmacol Exp Ther. 1983 Sep;226(3):686-700
references.pmid: 6310078
references.citation: Soc Sci Med. 1998 Jun;46(12):1569-85
references.pmid: 9672396
references.citation: Cochrane Database Syst Rev. 2007 Jul 18;(3):CD001851
references.pmid: 17636689
references.citation: J Affect Disord. 2000 Aug;59(2):119-26
references.pmid: 10837880
references.citation: BMJ. 1996 Nov 9;313(7066):1200
references.pmid: 8916759
references.citation: Ann Intern Med. 2000 May 2;132(9):743-56
references.pmid: 10787370
references.citation: J Clin Psychiatry. 2000 Dec;61(12):942-6
references.pmid: 11206600
references.citation: Pharmacoeconomics. 1998 Jan;13(1 Pt 2):157-69
references.pmid: 10184835
references.citation: World J Biol Psychiatry. 2002 Jan;3(1):5-43
references.pmid: 12479086
references.citation: J Gen Intern Med. 1999 Sep;14(9):569-80
references.pmid: 10491249
references.citation: CNS Drug Rev. 2001 Spring;7(1):1-24
references.pmid: 11420570
references.citation: J Clin Psychiatry. 2005 Mar;66(3):346-52
references.pmid: 15766301
references.citation: J Clin Psychiatry. 2000 Feb;61(2):95-100
references.pmid: 10732656
references.citation: N Engl J Med. 2007 Jun 7;356(23):2343-6
references.pmid: 17485726
references.citation: BMJ. 2003 May 31;326(7400):1167-70
references.pmid: 12775614
references.citation: J Clin Psychiatry. 2003 Aug;64(8):875-82
references.pmid: 12927001
references.citation: Aust N Z J Psychiatry. 2004 Jun;38(6):389-407
references.pmid: 15209830
references.citation: Int Clin Psychopharmacol. 2003 Jul;18(4):203-10
references.pmid: 12817154
references.citation: Cardiol Rev. 2006 Jul-Aug;14(4):164-9
references.pmid: 16788327
references.citation: J Clin Psychiatry. 2000 Aug;61(8):559-68
references.pmid: 10982198
references.citation: J Psychopharmacol. 1994 Jan;8(3):171-6
references.pmid: 22298585
references.citation: Int Clin Psychopharmacol. 2005 Jan;20(1):49-52
references.pmid: 15602117
references.citation: Int Clin Psychopharmacol. 1994 Summer;9(2):95-100
references.pmid: 8057000
references.citation: J Clin Psychiatry. 2006 Nov;67(11):1674-81
references.pmid: 17196045
references.citation: Control Clin Trials. 2004 Dec;25(6):598-612
references.pmid: 15588746
references.citation: J Clin Psychiatry. 2005 Oct;66(10):1312-20
references.pmid: 16259546
references.citation: Am J Psychiatry. 1996 Dec;153(12):1631-3
references.pmid: 8942464
references.citation: Biol Psychiatry. 2000 Nov 1;48(9):894-901
references.pmid: 11074227
references.citation: Int Clin Psychopharmacol. 2000 Sep;15(5):263-71
references.pmid: 10993128
references.citation: BMJ. 2004 Apr 17;328(7445):939-43
references.pmid: 15087342
references.citation: J Psychopharmacol. 1999 Dec;13(4):406-14
references.pmid: 10667618
references.citation: Psychopharmacol Bull. 1997;33(1):101-3
references.pmid: 9133758
references.citation: J Clin Psychopharmacol. 2002 Apr;22(2):137-47
references.pmid: 11910258
references.citation: JAMA. 2007 Jan 24;297(4):367-79
references.pmid: 17244833
references.citation: J Clin Psychiatry. 1988 Aug;49 Suppl:40-5
references.pmid: 3045112
references.citation: Clin Evid. 2004 Dec;(12):1391-436
references.pmid: 15865725
references.citation: J Affect Disord. 2000 Aug;59(2):149-57
references.pmid: 10837883
references.citation: BMJ. 2007 Feb 3;334(7587):215-6
references.pmid: 17272528
references.citation: J Clin Psychiatry. 1997 Dec;58(12):532-7
references.pmid: 9448656
references.citation: Lancet. 2009 Feb 28;373(9665):746-58
references.pmid: 19185342
references.citation: Br J Psychiatry. 2002 May;180:396-404
references.pmid: 11983635
references.citation: Clin Ther. 1999 Apr;21(4):643-58
references.pmid: 10363731
references.citation: Can Fam Physician. 2002 May;48:905-12
references.pmid: 12053635
references.citation: BMJ. 2002 Nov 2;325(7371):991
references.pmid: 12411354
references.citation: BMJ. 2003 Sep 6;327(7414):557-60
references.pmid: 12958120
references.citation: Cochrane Database Syst Rev. 2007;(2):
references.pmid: 25267892